DNMT3B Oncogenic Activity in Human Intestinal Cancer Is Not Linked to CIMP or BRAFV600E Mutation

• Published in: iScience Vol. 23; no. 2; p. 100838
• Main Authors: MacKenzie, Douglas J., Robertson, Neil A., Rather, Iqbal, Reid, Claire, Sendzikaite, Gintare, Cruickshanks, Hazel, McBryan, Tony, Hodges, Andrew, Pritchard, Catrin, Blyth, Karen, Adams, Peter D.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 21.02.2020; Elsevier
• Subjects: Biological Sciences; Cancer; Molecular Biology; Molecular Biology; Biological Sciences; Cancer
• ISSN: 2589-0042; 2589-0042
• DOI: 10.1016/j.isci.2020.100838

Approximately 10% of human colorectal cancer (CRC) are associated with activated BRAFV600E mutation, typically in absence of APC mutation and often associated with a CpG island methylator (CIMP) phenotype. To protect from cancer, normal intestinal epithelial cells respond to oncogenic BRAFV600E by activation of intrinsic p53 and p16-dependent tumor suppressor mechanisms, such as cellular senescence. Conversely, CIMP is thought to contribute to bypass of these tumor suppressor mechanisms, e.g. via epigenetic silencing of tumor suppressor genes, such as p16. It has been repeatedly proposed that DNMT3B is responsible for BRAFV600E-induced CIMP in human CRC. Here we set out to test this by in silico, in vitro, and in vivo approaches. We conclude that although both BRAFV600E and DNMT3B harbor oncogenic potential in vitro and in vivo and show some evidence of cooperation in tumor promotion, they do not frequently cooperate to promote CIMP and human intestinal cancer. [Display omitted] •DNMT3B antagonizes BRAFV600E-induced senescence-like state•DNMT3B accelerates BRAFV600E-induced intestinal cancer•Other studies do not support a role for DNMT3B in CIMP and cooperation with BRAFV600E•On balance, BRAFV600E and DNMT3B are unlikely to cooperate in human intestinal cancer Biological Sciences; Molecular Biology; Cancer